当前位置: X-MOL 学术Eur. J. Med. Chem. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of PT-65 as a highly potent and selective Proteolysis-targeting chimera degrader of GSK3 for treating Alzheimer's disease
European Journal of Medicinal Chemistry ( IF 6.0 ) Pub Date : 2021-10-02 , DOI: 10.1016/j.ejmech.2021.113889
Lailiang Qu 1 , Shang Li 1 , Limei Ji 1 , Si Luo 1 , Ming Ding 1 , Fucheng Yin 1 , Cheng Wang 1 , Heng Luo 1 , Dehua Lu 1 , Xingchen Liu 1 , Wan Peng 1 , Lingyi Kong 1 , Xiaobing Wang 1
Affiliation  

GSK3 is a promising target for the treatment of Alzheimer's disease. Here, we describe the design and synthesize of a series of GSK3 degraders based on a click chemistry platform. A series of highly potent GSK3 degraders were obtained. Among them, PT-65 exhibited most potent degradation potency against GSK3α (DC50 = 28.3 nM) and GSK3β (DC50 = 34.2 nM) in SH-SY5Y cells. SPR assay confirmed that PT-65 binds to GSK3β with high affinity (KD = 12.41 nM). The proteomic study indicated that PT-65 could selectively induced GSK3 degradation. Moreover, PT-65 could effectively suppress GSK3β and Aβ mediated tau hyperphosphorylation in a dose-dependent manner and protect SH-SY5Y cells from Aβ caused cell damage. We also confirmed that PT-65 could suppress OA induced tau hyperphosphorylation and ameliorate learning and memory impairments in vivo model of AD. In summary, PT-65 might be a promising candidate for the treatment of AD.



中文翻译:

发现 PT-65 作为 GSK3 的高效和选择性蛋白水解靶向嵌合降解剂,用于治疗阿尔茨海默病

GSK3是治疗阿尔茨海默病的有希望的靶点。在这里,我们描述了基于点击化学平台的一系列 GSK3 降解剂的设计和合成。获得了一系列高效的 GSK3 降解剂。其中,PT-65 在 SH-SY5Y 细胞中对 GSK3α (DC 50  = 28.3 nM) 和 GSK3β (DC 50 = 34.2 nM) 表现出最强的降解效力。SPR 测定证实 PT-65 以高亲和力与 GSK3β 结合 (K D = 12.41 纳米)。蛋白质组学研究表明,PT-65 可以选择性地诱导 GSK3 降解。此外,PT-65 可有效抑制 GSK3β 和 Aβ 介导的 tau 过度磷酸化,并以剂量​​依赖性方式保护 SH-SY5Y 细胞免受 Aβ 引起的细胞损伤。我们还证实,PT-65 可以抑制 OA 诱导的 tau 过度磷酸化并改善 AD 体内模型中的学习和记忆障碍。总之,PT-65 可能是治疗 AD 的有希望的候选药物。

更新日期:2021-10-03
down
wechat
bug